Related Experiment Video

Updated: Jul 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Second-line therapeutic options in non-small-cell lung cancer

Johan Vansteenkiste1

  • 1Respiratory Oncology Unit, Department of Pulmonology, University Hospital Leuven, Leuven Lung Cancer Group, Leuven, Belgium. Johan.Vansteenkiste@uz.kuleuven.ac.be

Lung Cancer (Amsterdam, Netherlands)
|October 27, 2006
PubMed

Insights

Advances in non-small-cell lung cancer (NSCLC) treatment show improved outcomes for second-line therapy. Identifying optimal NSCLC treatment sequences remains a key challenge for clinicians.

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Therapeutics

Background:

  • Non-small-cell lung cancer (NSCLC) historically had a poor prognosis, especially after first-line chemotherapy.
  • Second-line therapy for NSCLC was not a significant clinical consideration a decade ago.
  • Recent advancements have improved survival rates and response to NSCLC treatment.

Purpose of the Study:

  • To review the progress in second-line therapy for non-small-cell lung cancer.
  • To discuss the evolving landscape of NSCLC treatment strategies.
  • To highlight the challenges in sequencing second-line therapies for NSCLC patients.

Main Methods:

  • Review of clinical data and treatment guidelines for NSCLC.
  • Analysis of survival rates and response to various second-line regimens.
  • Discussion of evidence-based treatment sequencing in NSCLC.

Main Results:

  • Significant improvements in response rates, median survival, and 1-year survival for NSCLC patients receiving second-line treatment.
  • An expanding range of therapeutic options is now available for previously treated NSCLC patients.
  • Positive trends in managing advanced NSCLC with sequential therapies.

Conclusions:

  • Second-line therapy has become a viable and increasingly effective strategy in NSCLC management.
  • The primary challenge lies in selecting the optimal second-line regimen and its place in the overall treatment sequence.
  • Evidence-based sequencing is crucial for maximizing patient outcomes in NSCLC.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...